Damian Pharma

At DAMIAN, we believe that the true value of an idea lies in its real-world implementation. Our singular pursuit is to find therapeutic solutions for patients, matching distinct drug pharmacologies to well-characterized disease pathways. Putting compassion into action, DAMIAN is on a purposeful expedition to bring first-of-a-kind solutions for patients with aldosterone-dependent conditions. DAMIAN is a privately-held pharmaceutical company incorporated in Switzerland in 2015. Led by 3 industry veterans with 75+ years of experience developing innovative life-saving drugs, we execute our projects with the support of leading disease experts, clinical advisors, and established contract manufacturing and research organizations across the globe. We apply our deep expertise to our first indication, Primary Aldosteronism, which has a well-explained causality and a direct therapeutic target. DAMIAN is creating new solutions through our targeted drug, dexfadrostat phosphate (DP13), and diagnostic tracer, DP14. With perseverance and conviction, we endeavor to find therapeutic solutions wherever they exist, for the people who need them.